Sunshine Act could scare docs away from commercially-supported CME

Share this article:
Sunshine Act could scare docs away from commercially-supported CME
Sunshine Act could scare docs away from commercially-supported CME
A physician survey by the pro-commercial CME group CME Coalition found that docs are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest.

Asked if “attendance at a commercially-supported CME event was reported in a public, online government database as a ‘payment ‘ from the corporate supporter, would this affect your decision to attend CME courses?” three quarters of respondents said it would weigh on them at least “Somewhat,” and 47% answered “To a great extent.” Another 47% said the new disclosure requirements would affect their decision to participate as a panelist or presenter “To a great extent.” Two-thirds of the physicians surveyed said healthcare companies should be encouraged to support accredited CME through grants “To a great extent.”

The CME Coalition polled 515 physicians across the US. Ninety-four percent of those physicians had attended accredited CME events in the past year, and over half had attended four or more events. Two-thirds said CME was “Very important” in keeping up with clinical developments.

The Sunshine Act, a sweeping law aimed at promoting transparency in physician-industry relationships through mandated disclosures, was folded into the massive Affordable Care Act, which passed in March 2010. The Sunshine Act portions of the law have not yet gone into effect, as the Centers for Medicare & Medicaid Services (CMS), responsible for implementing the law, has repeatedly put off nailing down the details while it works on other portions of the ACA. These delays were the subject of a roundtable convened yesterday by one of the Sunshine Act's authors, Senate Committee on Aging chairman Herb Kohl (D-WI), in which CMS was harangued by Senators for putting the law on the back burner. CMS director of policy and data analysis Niall Brennan told the panel that CMS was “hopeful” to begin data collection sometime next year.  

“All of the stakeholders—consumer and industry groups together—want a fair rule and want it implemented now,” Sen. Kohl said in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...